docetaxel chemotherapy trang 2 tải miễn phí từ tailieunhanh

"docetaxel chemotherapy" trang 2 - tải miễn phí từ tailieunhanh

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial

7 27 1

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study

7 39 1

Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): Protocol of a multi-center, phase II study

Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): Protocol of a multi-center, phase II study

8 22 1

Protocol of OGSG 1901: A phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S−1 therapy

Protocol of OGSG 1901: A phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S−1 therapy

6 25 1

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma

10 1 1

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

8 34 1